Research programme: antimicrobial therapies - NovaBiotics

Drug Profile

Research programme: antimicrobial therapies - NovaBiotics

Alternative Names: Novamycin; Novarifyn; NP 339; NP 432; NP 525

Latest Information Update: 01 Feb 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NovaBiotics
  • Class Amino acids peptides and proteins; Antibacterials; Peptides; Peptidomimetics; Small molecules
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Clostridium-difficile-infections; Methicillin-resistant Staphylococcus aureus infections; Mycoses; Pseudomonal infections
  • No development reported Acne

Most Recent Events

  • 01 Feb 2018 Preclinical trials in Methicillin-resistant Staphylococcus aureus infections in United Kingdom (Inhalation) (NovaBiotics pipeline, February 2018)
  • 01 Feb 2018 Preclinical trials in Methicillin-resistant Staphylococcus aureus infections in United Kingdom (Topical) (NovaBiotics pipeline, February 2018)
  • 01 Feb 2018 NovaBiotics plans a clinical trial for NP 432 in 2019 (NovaBiotics pipeline, February 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top